Ya looking at the new 10 year stock incentive plan it definitely looks like they are putting things in place for a NP-Sintx merger when looking at the max number of employee shares. Sintx has the public listing, specialized materials with global patents, multitude of product candidates, and partners hidden behind NDAs. NP brings revenue primarily from Defense which is usually stable revenue, leadership, hopefully sales, and possibly manufacturing (several facilities in Canada & England).
NP's got the revenue, 60+m a year last i checked. I dont know if it has the positive cashflow to handle Sintx R&D costs or sales department needed to sell the implants. That said im sure its sales division can handle licensing deals.
Market Data 
Markets 
AI
